SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

SynOx Therapeutics

AmMax Bio is a competitor of SynOx Therapeutics in the field of developing monoclonal antibodies for the treatment of various diseases.

AmMax Bio

Deciphera is a competitor of SynOx Therapeutics in the development of targeted kinase inhibitors for the treatment of cancer and other diseases.

Deciphera

Daiichi Sankyo Company is a competitor of SynOx Therapeutics in the pharmaceutical industry, with a focus on developing a wide range of therapeutic products.

Daiichi Sankyo Company

SynOx Therapeutics is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. The company's mission is to establish emactuzumab as a best-in-class drug of choice to address unmet needs and improve the quality of life for as many patients as possible.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 1, 2024 7:51 PM	507dd814
public peers	general	May 1, 2024 7:51 PM	d2ee8b11
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 1, 2024 7:51 PM	70f334b6
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	beccd26c
crunchbase profile	general
li profile	general	May 1, 2024 7:51 PM	8936492d
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 1, 2024 7:51 PM	a0cf5217
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SYNOXTHERAPEUTICS

SynOx Therapeutics